Loading...

COVID‑19 Alert: Stay home if you feel unwell. If you have a fever, cough and difficulty breathing, seek medical attention. Follow the directions of your local health authority. Source WHO

We have a lockdown, "Working from HOME" Please reach out for any queries at: help@alliedmarketresearch.com & Int'l : +1-503-894-6022, (UK) : +44-845-528-1300

New

Anti-Viral Therapies Market by Type (Generic Drugs and Branded Drugs), Application (HIV, Hepatitis, Herpes Virus, Influenza, and Other Applications), and Mechanism of Action (Nucleotide Polymerase Inhibitor, Reverse Transcriptase Inhibitors, Protease Inhibitors, and Others): Global Opportunity Analysis and Industry Forecast, 2019-2026

A06278
Pages: 238
May 2020 | 1287 Views
 
Author(s) : Snehal Manjrekar, and Onkar Sumant
Tables: 115
Charts: 44
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Anti-viral Therapies Market

Request Now !

The global anti-viral therapies market size was valued at $38,316.5 million in 2018, and is projected to reach $46,213.4 million by 2026 registering a CAGR of 2.4% from 2019 to 2026.Anti-viral drugs are pharmaceutical products used in treating several viral infections by either eliminating the viral strain or restraining its ability to multiply and replicate within the human body. These drugs find applications in treating various diseases such as influenza, Hepatitis, HIV, and herpes. The use of anti-viral drugs in antiretroviral therapies and influenza anti-viral therapies for treatment of several viral diseases is expected to impact positively on the growth of the anti-viral therapies market. 

Anti-viral-Therapies-Market,-2019-2026_revised

Get more information on this report : Request Sample Pages

The global antiviral therapies market is majorly driven by increase in the incidence rate of viral infections. In addition, rise in R&D activities and development of newer & advanced formulations, such as vaccines and combination therapy along with pipeline products are expected to propel the market growth. However, high cost involved in the treatment and rise in demand for alternative medicines such as naturopathy and homeopathy are expected to restrain the market growth. On the contrary, development and approvals of combination therapies and growth opportunities in the emerging economies of Asia-Pacific and LAMEA regions are expected to provide numerous opportunities for the market growth during the forecast period.

Global Anti-viral Therapies Market segmentation

The global antiviral therapies market is segmented on the basis of application, type, mechanism of action, and region. Based on application, it is categorized into HIV, hepatitis, herpes, influenza, and other viral diseases. On the basis of type, it is classified into generic drugs and branded drugs. On the basis of mechanism of action, it is divided into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Application segment review

Based on application, it is categorized into HIV, hepatitis, herpes, influenza, and other viral diseases. HIV segment was the largest revenue contributor to the anti-viral therapies market in 2018 and is expected to continue to this trend during the forecast period, owing to increase in incidences of HIV globally. For instance, as per the data published by UNAIDS, in 2017, around 37 million of the global population is living with HIV. The prevalence of HIV among the adults was estimated to be 0.8%. Therefore, increase in consumption of HIV anti-viral drugs for combating infection is the major factor that drives the growth of anti-viral therapies market for HIV segment.

Type segment review

On the basis of type, the anti-viral therapies market is classified into generic drugs and branded drugs. The branded drugs segment was a major revenue contributor to the anti-viral therapies market in 2018 and is expected to continue its dominance throughout the forecast period, owing to availability of large number of branded drugs for treating various viral infections. Furthermore, higher prescription rate accompanied with higher drug prices is ultimately resulting in high revenue generation. 

Anti-Viral Therapies Market
By Type

Your browser does not support the canvas element.

Branded drugs segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

Mechanism of action segment review

On the basis of mechanism of action, it is divided into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, and others. The reverse transcriptase inhibitors segment is expected to grow at the fastest CAGR during the forecast period, owing to increase in FDA drug approvals for treating viral infections by reverse transcriptase inhibitor mechanism.

North America dominated the global antiviral therapies market in 2018 and is expected to continue its dominance throughout the forecast period, owing to growth in incidences of infectious diseases across the region. For instance, as per the data published by CDC (Centers for Disease Control and Prevention), in 2020, the number of diagnoses of HIV infection in the U.S. were 38,281 (2017) and number of new hepatitis A, B, and C were 3,365, 3,409, and 4,225, respectively in 2017. Moreover, the number of deaths due to influenza were 6,515. In addition, the presence of well-established pharmaceutical players that are involved in the manufacturing of the anti-viral therapies and increase in awareness among the population are expected to drive the anti-viral therapies market growth in this region.

Anti-Viral Therapies Market
By Mechanism of Action

Your browser does not support the canvas element.

Nucleotide polymerase inhibitor segment holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Comprehensive competitive analysis and profiles of major market players such as F. Hoffmann-La Roche Ltd., Gilead Sciences, GlaxoSmithKline, Bristol-Myers-Squibb, Abbott Laboratories, AstraZeneca plc, AbbVie Inc., Aurobindo Pharma Limited, Johnson & Johnson, and Merck & Co., Inc. are provided in this report.

Key Benefits For Stakeholders

  • The anti-viral therapies market share and analysis is based on a comprehensive analysis of key developments in the biosensors industry.

  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the global anti-viral therapies market.

  • The study provides an in-depth analysis of the anti-viral therapies market trends to elucidate the imminent investment pockets.

  • The global anti-viral therapies market trends are studied from 2018 to 2026.

  • Information about the key drivers, restrains, and opportunities and their impact analysis on the anti-viral therapies market size is provided.

  • Porter’s five forces analysis illustrates the potency of the buyers and suppliers operating in the industry.

  • The quantitative analysis of the global anti-viral therapies market from 2019 to 2026 is provided to determine the market potential.

Key Market Segments

By Application

  • HIV 
  • Hepatitis 
  • Herpes Virus
  • Influenza
  • Other Applications

By Type

  • Generic Drugs
  • Branded Drugs

By Mechanism of Action

  • Nucleotide Polymerase Inhibitor
  • Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Market dynamics

3.3.1.Drivers

3.3.1.1.Surge in global burden of viral infection
3.3.1.2.Stronger pipeline of anti-viral drugs

3.3.2.Restraints

3.3.2.1.Higher cost of treatment

3.3.3.Opportunities

3.3.3.1.Increase in number of product approvals for combination therapy

CHAPTER 4:ANTI-VIRAL THERAPIES MARKET, BY APPLICATION

4.1.Overview

4.1.1.Market size and forecast

4.2.HIV

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Hepatitis

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country

4.4.Herpes virus

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country

4.5.Influenza

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country

4.6.Other Applications

4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by region
4.6.3.Market analysis, by country

CHAPTER 5:ANTI-VIRAL THERAPIES MARKET, BY TYPE

5.1.Overview

5.1.1.Market size and forecast

5.2.Generic drugs

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Branded drugs

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

CHAPTER 6:ANTI-VIRAL THERAPIES MARKET, BY MECHANISM OF ACTION

6.1.Overview

6.1.1.Market size and forecast

6.2.Nucleotide polymerase inhibitor

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Reverse transcriptase inhibitors

6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country

6.4.Protease inhibitors

6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country

6.5.Others

6.5.1.Market size and forecast, by region
6.5.2.Market analysis, by country

CHAPTER 7:GLOBAL ANTI-VIRAL THERAPIES MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends and opportunities
7.2.2.Market size and forecast, by type
7.2.3.Market size and forecast, by mechanism of action
7.2.4.Market size and forecast, by application
7.2.5.Market size and forecast, by country

7.2.5.1.U.S. market size and forecast, by type
7.2.5.2.U.S. Market size and forecast, by mechanism of action
7.2.5.3.U.S. market size and forecast, by application
7.2.5.4.Canada market size and forecast, by type
7.2.5.5.Canada Market size and forecast, by mechanism of action
7.2.5.6.Canada market size and forecast, by application
7.2.5.7.Mexico market size and forecast, by type
7.2.5.8.Mexico Market size and forecast, by mechanism of action
7.2.5.9.Mexico market size and forecast, by application

7.3.Europe

7.3.1.Key market trends and opportunities
7.3.2.Market size and forecast, by type
7.3.3.Market size and forecast, by mechanism of action
7.3.4.Market size and forecast, by application
7.3.5.Market size and forecast, by country

7.3.5.1.Germany market size and forecast, by type
7.3.5.2.Germany Market size and forecast, by mechanism of action
7.3.5.3.Germany market size and forecast, by application
7.3.5.4.France market size and forecast, by type
7.3.5.5.France Market size and forecast, by mechanism of action
7.3.5.6.France market size and forecast, by application
7.3.5.7.UK market size and forecast, by type
7.3.5.8.UK Market size and forecast, by mechanism of action
7.3.5.9.UK market size and forecast, by application
7.3.5.10.Italy market size and forecast, by type
7.3.5.11.Italy Market size and forecast, by mechanism of action
7.3.5.12.Italy market size and forecast, by application
7.3.5.13.Spain market size and forecast, by type
7.3.5.14.Spain Market size and forecast, by mechanism of action
7.3.5.15.Spain market size and forecast, by application
7.3.5.16.Rest of Europe market size and forecast, by type
7.3.5.17.Rest of Europe Market size and forecast, by mechanism of action
7.3.5.18.Rest of Europe market size and forecast, by application

7.4.Asia-Pacific

7.4.1.Key market trends and opportunities
7.4.2.Market size and forecast, by type
7.4.3.Market size and forecast, by mechanism of action
7.4.4.Market size and forecast, by application
7.4.5.Market size and forecast, by country
7.4.5.1.Japan market size and forecast, by type

7.4.5.2.Japan Market size and forecast, by mechanism of action
7.4.5.3.Japan market size and forecast, by application
7.4.5.4.China market size and forecast, by type
7.4.5.5.China Market size and forecast, by mechanism of action
7.4.5.6.China market size and forecast, by application
7.4.5.7.India market size and forecast, by type
7.4.5.8.India Market size and forecast, by mechanism of action
7.4.5.9.India market size and forecast, by application
7.4.5.10.Australia market size and forecast, by type
7.4.5.11.Australia Market size and forecast, by mechanism of action
7.4.5.12.Australia market size and forecast, by application
7.4.5.13.South Korea market size and forecast, by type
7.4.5.14.South Korea Market size and forecast, by mechanism of action
7.4.5.15.South Korea market size and forecast, by application
7.4.5.16.Rest of Asia-Pacific market size and forecast, by type
7.4.5.17.Rest of Asia-Pacific Market size and forecast, by mechanism of action
7.4.5.18.Rest of Asia-Pacific market size and forecast, by application

7.5.LAMEA

7.5.1.Key market trends and opportunities
7.5.2.Market size and forecast, by type
7.5.3.Market size and forecast, by mechanism of action
7.5.4.Market size and forecast, by application
7.5.5.Market size and forecast, by country

7.5.5.1.Brazil market size and forecast, by type
7.5.5.2.Brazil Market size and forecast, by mechanism of action
7.5.5.3.Brazil market size and forecast, by application
7.5.5.4.Saudi market size and forecast, by type
7.5.5.5.Saudi Market size and forecast, by mechanism of action
7.5.5.6.Saudi market size and forecast, by application
7.5.5.7.South Africa market size and forecast, by type
7.5.5.8.South Africa Market size and forecast, by mechanism of action
7.5.5.9.South Africa market size and forecast, by application
7.5.5.10.Rest of LAMEA market size and forecast, by type
7.5.5.11.Rest of LAMEA Market size and forecast, by mechanism of action
7.5.5.12.Rest of LAMEA market size and forecast, by application

CHAPTER 8:COMPANY PROFILES

8.1.Abbott Laboratories

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance

8.2.AbbVie Inc.

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Business performance
8.2.5.Key strategic moves and developments

8.3.Bristol Myers Squibb Company

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance

8.4.F. Hoffmann-La Roche Ltd.

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments

8.5.Johnson & Johnson

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Business performance

8.6.Merck & Co., Inc.

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Business performance
8.6.5.Key strategic moves and developments

8.7.GILEAD SCIENCES, INC.

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments

8.8.GlaxoSmithKline Plc.

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments

8.9.AstraZeneca PLC

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments

8.10.Aurobindo Pharma Limited

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance

LIST OF TABLES

TABLE 01.GLOBAL ANTI-VIRAL THERAPIES MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 02.HIV ANTI VIRAL THERAPIES MARKET BY REGION, 2018–2026 ($MILLION)
TABLE 03.HEPATITIS ANTI VIRAL THERAPIES MARKET BY REGION, 2018–2026 ($MILLION)
TABLE 04.HERPES VIRUS ANTI VIRAL THERAPIES MARKET BY REGION, 2018–2026 ($MILLION)
TABLE 05.INFLUENZA ANTI VIRAL THERAPIES MARKET BY REGION, 2018–2026 ($MILLION)
TABLE 06.OTHER APPLICATIONS ANTI VIRAL THERAPIES MARKET BY REGION, 2018–2026 ($MILLION)
TABLE 07.GLOBAL ANTI-VIRAL THERAPIES MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 08.ANTI-VIRAL THERAPIES MARKET FOR GENERIC DRUGS, BY REGION, 2018–2026 ($MILLION)
TABLE 09.ANTI-VIRAL THERAPIES MARKET FOR BRANDED DRUGS, BY REGION, 2018–2026 ($MILLION)
TABLE 10.GLOBAL ANTI-VIRAL THERAPIES MARKET, BY MECHANISM OF ACTION, 2018–2026 ($MILLION)
TABLE 11.ANTI-VIRAL THERAPIES MARKET, FOR NUCLEOTIDE POLYMERASE INHIBITOR, BY REGION, 2018–2026 ($MILLION)
TABLE 12.ANTI-VIRAL THERAPIES MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018–2026 ($MILLION)
TABLE 13.ANTI-VIRAL THERAPIES MARKET FOR PROTEASE INHIBITORS, BY REGION, 2018–2026 ($MILLION)
TABLE 14.ANTI-VIRAL THERAPIES MARKET FOR OTHERS, BY REGION, 2018–2026 ($MILLION)
TABLE 15.GLOBAL ANTI-VIRAL THERAPIES MARKET BY REGION, 2018-2026, ($MILLION)
TABLE 16.NORTH AMERICA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 17.NORTH AMERICA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 18.NORTH AMERICA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 19.NORTH AMERICA ANTI-VIRAL THERAPIES MARKET BY COUNTRY, 2018-2026, ($MILLION)
TABLE 20.U.S. ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 21.U.S. ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 22.U.S. ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 23.CANADA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 24.CANADA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 25.CANADA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 26.MEXICO ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 27.MEXICO ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 28.MEXICO ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 29.EUROPE ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 30.EUROPE ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 31.EUROPE ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 32.EUROPE ANTI-VIRAL THERAPIES MARKET BY COUNTRY, 2018-2026, ($MILLION)
TABLE 33.GERMANY ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 34.GERMANY ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 35.GERMANY ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 36.FRANCE ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 37.FRANCE ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 38.FRANCE ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 39.UK ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 40.UK ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 41.UK ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 42.ITALY ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 43.ITALY ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 44.ITALY ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 45.SPAIN ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 46.SPAIN ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 47.SPAIN ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 48.REST OF EUROPE ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 49.REST OF EUROPE ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 50.REST OF EUROPE ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 51.ASIA-PACIFIC ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 52.ASIA-PACIFIC ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 53.ASIA-PACIFIC ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 54.ASIA-PACIFIC ANTI-VIRAL THERAPIES MARKET BY COUNTRY, 2018-2026, ($MILLION)
TABLE 55.JAPAN ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 56.JAPAN ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 57.JAPAN ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 58.CHINA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 59.CHINA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 60.CHINA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 61.INDIA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 62.INDIA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 63.INDIA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 64.AUSTRALIA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 65.AUSTRALIA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 66.AUSTRALIA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 67.SOUTH KOREA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 68.SOUTH KOREA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 69.SOUTH KOREA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 70.REST OF ASIA-PACIFIC ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 71.REST OF ASIA-PACIFIC ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 72.REST OF ASIA-PACIFIC ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 73.LAMEA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 74.LAMEA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 75.LAMEA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 76.LAMEA ANTI-VIRAL THERAPIES MARKET BY COUNTRY, 2018-2026, ($MILLION)
TABLE 77.BRAZIL ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 78.BRAZIL ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 79.BRAZIL ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 80.SAUDI ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 81.SAUDI ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 82.SAUDI ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 83.SOUTH AFRICA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 84.SOUTH AFRICA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 85.SOUTH AFRICA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 86.REST OF LAMEA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 87.REST OF LAMEA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 88.REST OF LAMEA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 89.ABBOTT: COMPANY SNAPSHOT
TABLE 90.ABBOTT: OPERATING SEGMENTS
TABLE 91.ABBOTT: PRODUCT PORTFOLIO
TABLE 92.ABBVIE: COMPANY SNAPSHOT
TABLE 93.ABBVIE: OPERATING SEGMENTS
TABLE 94.BMS: COMPANY SNAPSHOT
TABLE 95.BMS: OPERATING SEGMENTS
TABLE 96.BMS: PRODUCT PORTFOLIO
TABLE 97.ROCHE: COMPANY SNAPSHOT
TABLE 98.ROCHE: OPERATING SEGMENTS
TABLE 99.ROCHE: PRODUCT PORTFOLIO
TABLE 100.J&J: COMPANY SNAPSHOT
TABLE 101.J&J: OPERATING SEGMENTS
TABLE 102.MERCK: COMPANY SNAPSHOT
TABLE 103.MERCK: OPERATING SEGMENTS
TABLE 104.GILEAD: COMPANY SNAPSHOT
TABLE 105.GILEAD: OPERATING SEGMENTS
TABLE 106.GILEAD: PRODUCT PORTFOLIO
TABLE 107.GSK.: COMPANY SNAPSHOT
TABLE 108.GSK: OPERATING SEGMENTS
TABLE 109.GSK: PRODUCT PORTFOLIO
TABLE 110.ASTRAZENECA: COMPANY SNAPSHOT
TABLE 111.ASTRAZENECA: OPERATING SEGMENTS
TABLE 112.ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 113.AUROBINDO: COMPANY SNAPSHOT
TABLE 114.AUROBINDO: OPERATING SEGMENTS
TABLE 115.AUROBINDO: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.ANTI-VIRAL THERAPIES MARKET SEGMENTATION
FIGURE 01.TOP INVESTMENT POCKETS
FIGURE 02.TOP WINNING STRATEGIES, BY YEAR, 2016-2019*
FIGURE 03.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2016-2019* (%)
FIGURE 04.TOP WINNING STRATEGIES, BY COMPANY, 2016-2019*
FIGURE 05.TOP IMPACTING FACTORS
FIGURE 06.COMPARATIVE ANALYSIS OF HIV ANTI VIRAL THERAPIES MARKET BY COUNTRY, 2018 & 2026 (%)
FIGURE 07.COMPARATIVE ANALYSIS OF HEPATITIS ANTI VIRAL THERAPIES MARKE BY COUNTRY, 2018 & 2026 (%)
FIGURE 08.COMPARATIVE ANALYSIS OF HERPES VIRUS ANTI VIRAL THERAPIES MARKET BY COUNTRY, 2018 & 2026 (%)
FIGURE 09.COMPARATIVE ANALYSIS OF INFLUENZA ANTI VIRAL THERAPIES MARKET BY COUNTRY, 2018 & 2026 (%)
FIGURE 10.COMPARATIVE ANALYSIS OF OTHER APPLICATIONS ANTI VIRAL THERAPIES MARKET BY COUNTRY, 2018 & 2026 (%)
FIGURE 11.ANTI-VIRAL THERAPIES FOR GENERIC DRUGS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12.ANTI-VIRAL THERAPIES MARKET FOR BRANDED DRUGS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 13.COMPARATIVE ANALYSIS OF ANTI-VIRAL THERAPIES MARKET, FOR NUCLEOTIDE POLYMERASE INHIBITOR BY COUNTRY, 2018 & 2026 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF ANTI-VIRAL THERAPIES MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF ANTI-VIRAL THERAPIES MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF ANTI-VIRAL THERAPIES MARKET FOR OTHERS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 17.ABBOTT: NET SALES, 2016–2018 ($MILLION)
FIGURE 18.ABBOTT: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 19.ABBOTT: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 20.ABBVIE: NET SALES, 2016–2018 ($MILLION)
FIGURE 21.ABBVIE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 22.ABBVIE: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 23.BMS: NET SALES, 2016–2018 ($MILLION)
FIGURE 24.BMS: REVENUE SHARE BY SEGMENT, 2018(%)
FIGURE 25.BMS: REVENUE SHARE BY REGION, 2018(%)
FIGURE 26.ROCHE: NET SALES, 2016–2018 ($MILLION)
FIGURE 27.ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 28.ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 29.J&J: NET SALES, 2016–2018 ($MILLION)
FIGURE 30.J&J: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 31.J&J: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 32.MERCK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 33.MERCK: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 34.GILEAD: REVENUE, 2016-2018($MILLION)
FIGURE 35.GILEAD: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 36.GSK: REVENUE, 2016-2018($MILLION)
FIGURE 37.GSK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 38.GSK: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 39.ASTRAZENECA: NET SALES, 2016–2018 ($THOUSAND)
FIGURE 40.ASTRAZENECA: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 41.ASTRAZENECA: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 42.AUROBINDO: NET SALES, 2016–2018 ($MILLION)
FIGURE 43.AUROBINDO: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 44.AUROBINDO: REVENUE SHARE BY REGION, 2018 (%)

 
 

The factors that drivethe growth of the anti-viral therapies market includeupsurge in occurrence of infectious diseases in the developed as well as developing region across the globe. Beside this, the presence of strong pipeline drugs for treating viral infections are expectedto augment the growth of the anti-viral therapies market. In contrast to these factors, treating viral infections can incur huge costs to the patients. Moreover, the ever-changing preferences of the patients toward different therapies such as homeopathy and naturopathy are expected to restrain the development of the market. On the other hand, developing novel therapies by combining different drugs are projected to offer lucrativeopportunities for the expansion of the anti-viral therapies market in the near future.

Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America is dominating the global antiviral therapies market in 2018 and is expected to continue its dominance throughout the forecast period, owing to growth inincidences of infectious diseases across the region. Whereas, Asia-Pacific is expected to grow at the fastest CAGR during the forecast period due to presence of several generic pharmaceutical players and increase in investmentsfor drug development in South Asian countries. 

 

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library,  T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
 

A. The total market value of Anti-viral Therapies Market is $46,213.4 million in 2018.

A. The forecast period for Anti-viral Therapies Market is 2019 to 2026

A. The market value of Anti-viral Therapies Market in 2019 is $39,224.6 million

A. The base year is 2018 in Anti-viral Therapies Market

A. Top companies such as, F. Hoffmann-La Roche Ltd., Gilead Sciences, GlaxoSmithKline, Bristol-Myers-Squibb, Abbott Laboratories, AstraZeneca plc, held a high market position in 2018.

A. Nucleotide polymerase inhibitor segment is the most influencing segment growing in the Anti-viral Therapies Market

A. The key trend in the Anti-viral Therapies Market is increase in the incidence rate of viral infections across the globe which drives the growth of the market.

A. Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as China and India with a CAGR of 3.3% and 3.0% respectively.

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Anti-Viral Therapies Market

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/m
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library.  T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts